DK162624B - Fremgangsmaade til fremstilling af et guargummi-holdigt produkt - Google Patents
Fremgangsmaade til fremstilling af et guargummi-holdigt produkt Download PDFInfo
- Publication number
- DK162624B DK162624B DK287386A DK287386A DK162624B DK 162624 B DK162624 B DK 162624B DK 287386 A DK287386 A DK 287386A DK 287386 A DK287386 A DK 287386A DK 162624 B DK162624 B DK 162624B
- Authority
- DK
- Denmark
- Prior art keywords
- solvent
- process according
- film
- guar gum
- propanol
- Prior art date
Links
- 238000000034 method Methods 0.000 title claims description 19
- 238000004519 manufacturing process Methods 0.000 title abstract 2
- 229920002907 Guar gum Polymers 0.000 claims abstract description 23
- 239000000665 guar gum Substances 0.000 claims abstract description 23
- 229960002154 guar gum Drugs 0.000 claims abstract description 23
- 235000010417 guar gum Nutrition 0.000 claims abstract description 23
- 239000002904 solvent Substances 0.000 claims abstract description 15
- 239000002245 particle Substances 0.000 claims abstract description 13
- 229920000642 polymer Polymers 0.000 claims abstract description 7
- 150000001875 compounds Chemical class 0.000 claims abstract description 6
- 235000013312 flour Nutrition 0.000 claims abstract description 6
- 239000003960 organic solvent Substances 0.000 claims abstract description 6
- 239000007900 aqueous suspension Substances 0.000 claims abstract description 5
- 235000014113 dietary fatty acids Nutrition 0.000 claims abstract description 5
- 239000000194 fatty acid Substances 0.000 claims abstract description 5
- 229930195729 fatty acid Natural products 0.000 claims abstract description 5
- 150000004665 fatty acids Chemical class 0.000 claims abstract description 5
- 239000001856 Ethyl cellulose Substances 0.000 claims abstract description 4
- ZZSNKZQZMQGXPY-UHFFFAOYSA-N Ethyl cellulose Chemical compound CCOCC1OC(OC)C(OCC)C(OCC)C1OC1C(O)C(O)C(OC)C(CO)O1 ZZSNKZQZMQGXPY-UHFFFAOYSA-N 0.000 claims abstract description 4
- 229920001249 ethyl cellulose Polymers 0.000 claims abstract description 4
- 235000019325 ethyl cellulose Nutrition 0.000 claims abstract description 4
- 230000008961 swelling Effects 0.000 claims abstract description 4
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims abstract description 4
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 claims description 21
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 claims description 14
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 11
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical group ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 claims description 9
- ZWEHNKRNPOVVGH-UHFFFAOYSA-N 2-Butanone Chemical group CCC(C)=O ZWEHNKRNPOVVGH-UHFFFAOYSA-N 0.000 claims description 6
- YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 claims description 6
- 125000004432 carbon atom Chemical group C* 0.000 claims description 5
- UHOVQNZJYSORNB-UHFFFAOYSA-N monobenzene Natural products C1=CC=CC=C1 UHOVQNZJYSORNB-UHFFFAOYSA-N 0.000 claims description 5
- 229920000623 Cellulose acetate phthalate Polymers 0.000 claims description 3
- 229920001800 Shellac Polymers 0.000 claims description 3
- 125000002091 cationic group Chemical group 0.000 claims description 3
- 229940081734 cellulose acetate phthalate Drugs 0.000 claims description 3
- 229920001577 copolymer Polymers 0.000 claims description 3
- 230000003111 delayed effect Effects 0.000 claims description 3
- 125000005397 methacrylic acid ester group Chemical group 0.000 claims description 3
- 239000000203 mixture Substances 0.000 claims description 3
- 230000007935 neutral effect Effects 0.000 claims description 3
- ZLGIYFNHBLSMPS-ATJNOEHPSA-N shellac Chemical compound OCCCCCC(O)C(O)CCCCCCCC(O)=O.C1C23[C@H](C(O)=O)CCC2[C@](C)(CO)[C@@H]1C(C(O)=O)=C[C@@H]3O ZLGIYFNHBLSMPS-ATJNOEHPSA-N 0.000 claims description 3
- 239000004208 shellac Substances 0.000 claims description 3
- 229940113147 shellac Drugs 0.000 claims description 3
- 235000013874 shellac Nutrition 0.000 claims description 3
- 229920003067 (meth)acrylic acid ester copolymer Polymers 0.000 claims description 2
- JKNCOURZONDCGV-UHFFFAOYSA-N 2-(dimethylamino)ethyl 2-methylprop-2-enoate Chemical compound CN(C)CCOC(=O)C(C)=C JKNCOURZONDCGV-UHFFFAOYSA-N 0.000 claims description 2
- CTQNGGLPUBDAKN-UHFFFAOYSA-N O-Xylene Chemical compound CC1=CC=CC=C1C CTQNGGLPUBDAKN-UHFFFAOYSA-N 0.000 claims description 2
- 229920002494 Zein Polymers 0.000 claims description 2
- GAMPNQJDUFQVQO-UHFFFAOYSA-N acetic acid;phthalic acid Chemical compound CC(O)=O.OC(=O)C1=CC=CC=C1C(O)=O GAMPNQJDUFQVQO-UHFFFAOYSA-N 0.000 claims description 2
- 125000000129 anionic group Chemical group 0.000 claims description 2
- 150000001491 aromatic compounds Chemical class 0.000 claims description 2
- 239000001866 hydroxypropyl methyl cellulose Substances 0.000 claims description 2
- 229920003088 hydroxypropyl methyl cellulose Polymers 0.000 claims description 2
- 235000010979 hydroxypropyl methyl cellulose Nutrition 0.000 claims description 2
- UFVKGYZPFZQRLF-UHFFFAOYSA-N hydroxypropyl methyl cellulose Chemical compound OC1C(O)C(OC)OC(CO)C1OC1C(O)C(O)C(OC2C(C(O)C(OC3C(C(O)C(O)C(CO)O3)O)C(CO)O2)O)C(CO)O1 UFVKGYZPFZQRLF-UHFFFAOYSA-N 0.000 claims description 2
- 150000002576 ketones Chemical class 0.000 claims description 2
- 229940100467 polyvinyl acetate phthalate Drugs 0.000 claims description 2
- 239000008096 xylene Substances 0.000 claims description 2
- 239000005019 zein Substances 0.000 claims description 2
- 229940093612 zein Drugs 0.000 claims description 2
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical group OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 claims 3
- DKGAVHZHDRPRBM-UHFFFAOYSA-N Tert-Butanol Chemical compound CC(C)(C)O DKGAVHZHDRPRBM-UHFFFAOYSA-N 0.000 claims 2
- BDERNNFJNOPAEC-UHFFFAOYSA-N propan-1-ol Chemical compound CCCO BDERNNFJNOPAEC-UHFFFAOYSA-N 0.000 claims 2
- CXKLIELNANLEIH-UHFFFAOYSA-N CC(=C)C(O)=O.CC=C(C)C(O)=O Chemical compound CC(=C)C(O)=O.CC=C(C)C(O)=O CXKLIELNANLEIH-UHFFFAOYSA-N 0.000 claims 1
- 229930195733 hydrocarbon Natural products 0.000 claims 1
- 150000002430 hydrocarbons Chemical class 0.000 claims 1
- 229920000831 ionic polymer Polymers 0.000 claims 1
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims 1
- 230000002459 sustained effect Effects 0.000 abstract 1
- 239000000047 product Substances 0.000 description 12
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 10
- 239000003795 chemical substances by application Substances 0.000 description 6
- 235000012000 cholesterol Nutrition 0.000 description 4
- 230000000694 effects Effects 0.000 description 4
- 238000005054 agglomeration Methods 0.000 description 3
- 230000002776 aggregation Effects 0.000 description 3
- 238000005469 granulation Methods 0.000 description 3
- 230000003179 granulation Effects 0.000 description 3
- 150000002632 lipids Chemical class 0.000 description 3
- OMDQUFIYNPYJFM-XKDAHURESA-N (2r,3r,4s,5r,6s)-2-(hydroxymethyl)-6-[[(2r,3s,4r,5s,6r)-4,5,6-trihydroxy-3-[(2s,3s,4s,5s,6r)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxyoxan-2-yl]methoxy]oxane-3,4,5-triol Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@@H]1OC[C@@H]1[C@@H](O[C@H]2[C@H]([C@@H](O)[C@H](O)[C@@H](CO)O2)O)[C@H](O)[C@H](O)[C@H](O)O1 OMDQUFIYNPYJFM-XKDAHURESA-N 0.000 description 2
- MUZDXNQOSGWMJJ-UHFFFAOYSA-N 2-methylprop-2-enoic acid;prop-2-enoic acid Chemical class OC(=O)C=C.CC(=C)C(O)=O MUZDXNQOSGWMJJ-UHFFFAOYSA-N 0.000 description 2
- 206010010774 Constipation Diseases 0.000 description 2
- 244000007835 Cyamopsis tetragonoloba Species 0.000 description 2
- 229920000926 Galactomannan Polymers 0.000 description 2
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 2
- 210000001035 gastrointestinal tract Anatomy 0.000 description 2
- 238000001879 gelation Methods 0.000 description 2
- 239000008103 glucose Substances 0.000 description 2
- IPCSVZSSVZVIGE-UHFFFAOYSA-N hexadecanoic acid Chemical compound CCCCCCCCCCCCCCCC(O)=O IPCSVZSSVZVIGE-UHFFFAOYSA-N 0.000 description 2
- 235000020845 low-calorie diet Nutrition 0.000 description 2
- 230000008092 positive effect Effects 0.000 description 2
- 239000000843 powder Substances 0.000 description 2
- UUGXDEDGRPYWHG-UHFFFAOYSA-N (dimethylamino)methyl 2-methylprop-2-enoate Chemical compound CN(C)COC(=O)C(C)=C UUGXDEDGRPYWHG-UHFFFAOYSA-N 0.000 description 1
- WQZGKKKJIJFFOK-QTVWNMPRSA-N D-mannopyranose Chemical group OC[C@H]1OC(O)[C@@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-QTVWNMPRSA-N 0.000 description 1
- 206010011878 Deafness Diseases 0.000 description 1
- 206010012735 Diarrhoea Diseases 0.000 description 1
- 241000220485 Fabaceae Species 0.000 description 1
- CERQOIWHTDAKMF-UHFFFAOYSA-N Methacrylic acid Chemical compound CC(=C)C(O)=O CERQOIWHTDAKMF-UHFFFAOYSA-N 0.000 description 1
- 235000021314 Palmitic acid Nutrition 0.000 description 1
- 235000021355 Stearic acid Nutrition 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- WQZGKKKJIJFFOK-PHYPRBDBSA-N alpha-D-galactose Chemical compound OC[C@H]1O[C@H](O)[C@H](O)[C@@H](O)[C@H]1O WQZGKKKJIJFFOK-PHYPRBDBSA-N 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 230000017531 blood circulation Effects 0.000 description 1
- 235000013339 cereals Nutrition 0.000 description 1
- 150000008280 chlorinated hydrocarbons Chemical class 0.000 description 1
- 239000011248 coating agent Substances 0.000 description 1
- 238000000576 coating method Methods 0.000 description 1
- 230000001934 delay Effects 0.000 description 1
- 206010012601 diabetes mellitus Diseases 0.000 description 1
- 210000003238 esophagus Anatomy 0.000 description 1
- 239000000835 fiber Substances 0.000 description 1
- 239000012467 final product Substances 0.000 description 1
- 206010016766 flatulence Diseases 0.000 description 1
- 239000012530 fluid Substances 0.000 description 1
- 235000013305 food Nutrition 0.000 description 1
- 229960003082 galactose Drugs 0.000 description 1
- 150000004676 glycans Chemical class 0.000 description 1
- 238000010438 heat treatment Methods 0.000 description 1
- 235000003642 hunger Nutrition 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 229940063559 methacrylic acid Drugs 0.000 description 1
- -1 methylchlond Chemical compound 0.000 description 1
- WQEPLUUGTLDZJY-UHFFFAOYSA-N n-Pentadecanoic acid Natural products CCCCCCCCCCCCCCC(O)=O WQEPLUUGTLDZJY-UHFFFAOYSA-N 0.000 description 1
- QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 1
- OQCDKBAXFALNLD-UHFFFAOYSA-N octadecanoic acid Natural products CCCCCCCC(C)CCCCCCCCC(O)=O OQCDKBAXFALNLD-UHFFFAOYSA-N 0.000 description 1
- 229920001282 polysaccharide Polymers 0.000 description 1
- 239000005017 polysaccharide Substances 0.000 description 1
- 239000007858 starting material Substances 0.000 description 1
- 239000008117 stearic acid Substances 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 229940124024 weight reducing agent Drugs 0.000 description 1
- 239000013585 weight reducing agent Substances 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
- A23L2/00—Non-alcoholic beverages; Dry compositions or concentrates therefor; Preparation or treatment thereof
- A23L2/52—Adding ingredients
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
- A23L29/00—Foods or foodstuffs containing additives; Preparation or treatment thereof
- A23L29/20—Foods or foodstuffs containing additives; Preparation or treatment thereof containing gelling or thickening agents
- A23L29/206—Foods or foodstuffs containing additives; Preparation or treatment thereof containing gelling or thickening agents of vegetable origin
- A23L29/238—Foods or foodstuffs containing additives; Preparation or treatment thereof containing gelling or thickening agents of vegetable origin from seeds, e.g. locust bean gum or guar gum
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/20—Reducing nutritive value; Dietetic products with reduced nutritive value
- A23L33/21—Addition of substantially indigestible substances, e.g. dietary fibres
Landscapes
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Polymers & Plastics (AREA)
- Health & Medical Sciences (AREA)
- Nutrition Science (AREA)
- Engineering & Computer Science (AREA)
- Food Science & Technology (AREA)
- Mycology (AREA)
- Dispersion Chemistry (AREA)
- Polysaccharides And Polysaccharide Derivatives (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Compositions Of Macromolecular Compounds (AREA)
- Jellies, Jams, And Syrups (AREA)
- Coloring Foods And Improving Nutritive Qualities (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Processes Of Treating Macromolecular Substances (AREA)
Description
DK 162624 B
Opfindelsen angår en fremgangsmåde til fremstilling af et produkt omfattende guargummi i form af partikler med forsinket kvældning i vandig suspension. Opfindelsens formål er at angive en fremgangsmåde, ved hjælp af hvilken guar-5 gummi kan opnås i form af partikler, som har forsinket kvældning i vandig suspension, således at de kan indgives sikkert ved hjælp af en drikkelig suspension med lav viskositet .
Det er tidligere kendt at indgive guargummi til mennesker 10 med flere forskellige formål. Således kan guargummi, som kvælder op i vandig suspension, anvendes som middel for overvægtige personer til at nedsætte sult fornemmelsen, der frembringes, når de er på lavkaloriediæt, og kan således virke som vægtreducerende middel. En bivirkning af 15 en lavkaloriediæt er meget ofte forstoppelse som med alle massefrie produkter. Guargummi har derved som alle masse-fiberprodukter en positiv virkning med hensyn til at forhindre forstoppelse. Det er også blevet påvist, at guargummi har en positiv virkning på sænkning af blodcholeste-20 rol, såkaldt lavdensitets-lipid-cholesterol (LDLC), også kaldt "den dårlige cholesterol", uden derved at ændre højdensitets-lipid-cholesterol (HDLC).
Betegnelsen guargummi betegner i denne beskrivelse med krav den formalede endosperm af korn af guarplanten, 25 Cyanopsis tetragonslobus, L. taub. (fam. Leguminosae).
Dette er et hvidt til gullighvidt, næsten farveløst pulver. Kemisk er det et hydrokolloidalt polysaccharid, ga-lactomannan, med høj molekylvægt. Det er beslægtet med galactopyranose, som omfatter mannopyranoseenheder bundet 30 via glucosidiske bindinger, og hvoraf 75¾ er galacto- mannan.
Endvidere har det vist sig, at guargummi har indvirkning på glucosen i mavetarmkanalen, som forsinker dens absorp-
DK 162624 B
2 tion i blodcirkulationssystemet, hvilket betyder, at personer, som lider af diabetes, med fordel kan indtage guargummi og derved sænke sukkerbelastningen.
For at være i stand til at indgive guargummi er det 5 nødvendigt, at produktet ikke kvælder op og gelerer som almindeligt guarmel, da dette kan føre til uønskede bivirkninger i form af tilstoppende propper i oesophagus eller i mavetarmkanalen, eller man kan få et utiltalende geleagtigt produkt, som de fleste mennesker betragter 10 som vanskeligt at drikke.
Det har nu overraskende vist sig muligt at løse dette problem og opnå et godt virkende produkt ved hjælp af fremgangsmåden ifølge opfindelsen, som er ejendommelig ved, at pulverformet guargummi tilsættes en opløsning 15 af en organisk filmdannende forbindelse, valgt blandt filmdannende fedtsyrer, filmdannende polymere og ethyl-cellulose, i et organisk opløsningsmiddel med evne til at opløse den organiske filmdannende forbindelse eller i en blanding af vand og et sådant organisk opløsnings-20 middel i et volumenforhold på fra 60:40 til 0:100 under dannelse af partikelagglomerater med en størrelse på under 3 mm, men i det væsentlige over 0,5 mm.
Yderligere ejendommelige træk ifølge opfindelsen fremgår af de efterfølgende krav.
25 Betegnelsen "filmdannende fedtsyrer" betyder fedtsyrer med 14-20 carbonatomer, fortrinsvis stearinsyre og palmi-tinsyre.
Betegnelsen "filmdannende polymer" henfører til anioniske, kationiske og ikke-ioniske polymere, såsom celluloseace-30 tatphthalat, polyvinylacetatphthalat, hydroxypropylme- thylcelluloseacetatphthalat, shellak, zein, methacrylsyre- 3
DK 162624 B
methacrylsyremethylester-copolymer ("Eudragite ® L,S"), (r) acrylsyre-methacrylsyreestere ("Eudragitew RS,RL"), og copolymere af dimethylaminoethylmethacrylat og neutrale methacrylsyreestere ("Eudragite^ E").
5 Betegnelsen "organisk opløsningsmiddel" ovenfor henfører til opløsningsmidler, som opløser de nævnte organiske filmdannende midler, og som normalt anvendes inden for fødevareindustrien og den farmaceutiske industri. Sådanne opløsningsmidler er lavere alkanoler med 1-4 carbonato-10 mer, såsom ethanol og 2-propanol, lavere ketoner, såsom acetone og methylethylketon, chlorerede carbonhydrider, såsom methy lchlond, lavere aromatiske forbindelser med 6-8 carbonatomer, såsom benzen, xylen og toluen.
Det pulverformede udgangsmateriale har mest passende 15 en partikelstørrelse på under 150 ^um, fortrinsvis under 100 yum.
Partikelagglomerenngen - granuleringen - udføres fortrinsvis i en intensiv blander eller en kontinuert blander (NICA5YSTEM MIXER), hvorved det pulverformede guargummi-20 produkt tilsættes den nævnte opløsning i en mængde på 300-800 ml pr. kg guargummimel. Opløsningen indeholder normalt 2-30 vægt-% af det organiske filmdannende middel, mere typisk 6-9 vægt-S.
Fremgangsmåden forsyner guargummi-pulverpartiklerne 25 med et overtræk af det organiske filmdannende stof under samtidig agglomerering - granulering. Derpå tøres produktet, fortrinsvis i fluidiseret leje eller i varmeskab på bakker.
Denne agglomerering - granulering - ved fremgangsmåden 30 ifølge opfindelsen giver et slutprodukt, hvori alle partikelagglomeraterne er under 3 mm, og mindre end 4
DK 162624 B
5% er under 0,5 mm, og som har en geleringstid på over 5 min, men under 30 min, typisk 10-15 min ved en standardiseret prøvning med 10 g guargummiprodukt i 150 ml h^O ved 20 °C (6,25?ί opløsning).
5 Det har også vist sig, at produktet af fremgangsmåden ifølge opfindelsen har mindre bivirkninger end kendte guargummiprodukter, idet det medfører en lavere frekvens af flatulens og diarrhoea.
Til trods for behandlingen ved fremgangsmåden ifølge 10 opfindelsen opnås en god inhibering af glucose og en reduktion af lavdensitets-lipid-cholesterol (LDLC).
Fremgangsmåden ifølge opfindelsen belyses nærmere ved de efterfølgende eksempler.
EKSEMPEL 1 15 98,2 kg guargummimel med en partikelstørrelse på under 100 yura sattes til en opløsning bestående af vand og 2-propanol (azeotrop blanding 12:88) i en mængde på 28,5 kg, hvori der var opløst 9,18 kg ethylcellulose af kvaliteten N7-N50. Guargummimelet blev i en våd blander 20 (NICASYSTEM MIXER) befugtet øjeblikkeligt og tørret til et resterende h^O-indhold på under 8 vægt-% i et tørreapparat med fluidiseret leje i 30 min, hvorpå fraktionen med den rette partikelstørrelse 0,5^,a^3 mm, blev sigtet fra.
25 EKSEMPEL 2
Eksempel 1 blev gentaget med den forskel, at der anvendtes shellak som filmdannende middel, og opløsningsmidlet bestod af ethanol/acetone i volumenforholdet 50:50 (13 kg af hver) .
5
DK 162624 B
EKSEMPEL 3
Eksempel 1 blev/ gentaget med den forskel, at der anvendtes celluloseacetatphthalat som filmdannende middel, og opløsningsmidlet bestod af ethano1/acetone i volumen-5 forholdet 50:50 (13 kg af hver).
EKSEMPEL 4
Eksempel 1 blev gentaget med den forskel, at det filmdannende middel bestod af en kationisk filmdanner, "Eudra-æ\ gite^E", dvs. en polymer af dimethylaminomethylmethacry-10 lat og neutrale methacrylsyreestere, og opløsningsmidlet bestod af acetone/2-propanol i volumenforholdet 40:60.
EKSEMPEL 5
Eksempel 1 blev gentaget med den forskel, at det filmdannende middel bestod af en ikke-ionisk filmdanner, (r) 15 "Eudragite^ RS", dvs. en acrylsyre-methacrylsyreester-co- polymer, og opløsningsmidlet bestod af methylenchlo-nd/2-propanol i volumenforholdet 40:60.
Alle de ovenstående produkter havde en geleringstid på omkring 15 min ved den oven for anførte standardise-20 rede prøvning.
Claims (10)
1. Fremgangsmåde til fremstilling af et produkt omfattende guargummi i form af partikler med forsinket kvæld-ning i vandig suspension, kendetegnet ved, at guargummimel tilsættes en opløsning af en organisk 5 filmdannende forbindelse, valgt blandt filmdannende fedtsyrer, filmdannende polymere og ethylcellulose, i et organisk opløsningsmiddel med evne til at opløse den organiske filmdannende forbindelse eller i en blanding af vand og et sådant organisk opløsningsmiddel i et 10 volumenforhold på fra 60:40 til 0:100 under dannelse af partikelagglomerater med en størrelse på under 3 mm, men i det væsentlige over 0,5 mm.
2. Fremgangsmåde ifølge krav 1, kendetegnet ved, at opløsningsmidlet vælges blandt lavere 15 alkanoler med 1-4 carbonatomer, lavere ketoner, chlorerede lavere carbonhydrider og/eller lavere aromatiske forbindelser med 6-8 carbonatomer.
3. Fremgangsmåde ifølge krav 2, kendetegnet ved, at opløsningsmidlet vælges blandt methanol, 20 ethanol, 2-propanol, n-propanol og/eller tert.butanol.
4. Fremgangsmåde ifølge krav 2, kendetegnet ved, at opløsningsmidlet er methylethylketon og/eller acetone.
5. Fremgangsmåde ifølge krav 2, kendeteg- 25 net ved, at opløsningsmidlet er methylenchlorid. DK 162624 B
6. Fremgangsmåde ifølge krav 2, kendetegnet ved, at opløsningsmidlet er benzen, xylen og/eller toluen.
7. Fremgangsmåde ifølge krav 2 og 3, kendeteg net ved, at opløsningsmidlet er ethanol og acetone eller 2-propanol og acetone.
8. Fremgangsmåde ifølge krav 2 og b, kendeteg- 10 net ved, at opløsningsmidlet er 2-propanol og me- thylenchlorid.
9. Fremgangsmåde ifølge krav 1, kendetegnet ved, at udgangs-guargummimelet har en partikel- 15 størrelse på under 150 ^um, fortrinsvis under 100 ^um.
10. Fremgangsmåde ifølge krav 1, kendetegnet ved, at den filmdannende polymer er en anionisk, katiomsk og/eller ikke-ionisk polymer valgt blandt 20 celluloseacetatphthalat, polyvinylacetatphthalat, hydroxy- propylmethyIcelluloseacetatphthalat, shellak, zein, methacrylsyre-methacrylsyremethylester-copolymer, acrylsy-re-methacrylsyreester-copolymere og copolymere af dime-thylaminoethylmethacrylat og neutrale methacrylsyre-25 estere. 30 35
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| SE8503092A SE458576B (sv) | 1985-06-20 | 1985-06-20 | Foerfarande foer framstaellning av en guar-gum produkt |
| SE8503092 | 1985-06-20 |
Publications (4)
| Publication Number | Publication Date |
|---|---|
| DK287386D0 DK287386D0 (da) | 1986-06-19 |
| DK287386A DK287386A (da) | 1986-12-21 |
| DK162624B true DK162624B (da) | 1991-11-25 |
| DK162624C DK162624C (da) | 1992-04-13 |
Family
ID=20360668
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| DK287386A DK162624C (da) | 1985-06-20 | 1986-06-19 | Fremgangsmaade til fremstilling af et guargummi-holdigt produkt |
Country Status (8)
| Country | Link |
|---|---|
| US (1) | US4754027A (da) |
| EP (1) | EP0207032B1 (da) |
| AT (1) | ATE71493T1 (da) |
| DE (1) | DE3683412D1 (da) |
| DK (1) | DK162624C (da) |
| FI (1) | FI88101C (da) |
| NO (1) | NO164913C (da) |
| SE (1) | SE458576B (da) |
Families Citing this family (30)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB8628359D0 (en) * | 1986-11-27 | 1986-12-31 | Zyma Sa | Galenical formulation |
| US5288500A (en) * | 1987-03-13 | 1994-02-22 | Benzon Pharma A/S | Oral composition containing particles comprising an active substance |
| DK130287D0 (da) * | 1987-03-13 | 1987-03-13 | Benzon As Alfred | Oralt praeparat |
| US5466469A (en) * | 1988-06-28 | 1995-11-14 | Cibus Pharmaceutical, Inc. | Granular drug delivery system |
| JPH03120227A (ja) * | 1989-10-02 | 1991-05-22 | Shigeo Ochi | 飲食物消化分解産物吸収抑制剤 |
| US5721221A (en) * | 1991-03-08 | 1998-02-24 | Regents Of The University Of Minnesota | Lowering blood cholesterol levels using water soluble cellulose ethers |
| US5281584A (en) * | 1992-02-28 | 1994-01-25 | The Dow Chemical Company | Effect of particle-size distribution of cellulose ethers on palatability of compositions |
| US5645880A (en) * | 1993-07-08 | 1997-07-08 | Mcardle; Blaise | Protein-polysaccharide complex composition and method of use |
| JPH08512207A (ja) * | 1993-07-08 | 1996-12-24 | ブイピーピー コーポレイション | 食物繊維組成物、製造方法、及び使用 |
| US5591473A (en) * | 1993-07-08 | 1997-01-07 | Mcardle; Blaise | Protein-polysaccharide complex composition, method of preparation and use |
| US6395198B1 (en) | 1999-10-01 | 2002-05-28 | Mcardle Biaise | Anti-caking and anti-dusting composition and corresponding methods |
| US6818597B2 (en) | 2000-04-21 | 2004-11-16 | Benchmark Research & Technology, Inc. | Suspensions of water soluble polymers in surfactant free non-aqueous solvents |
| US6586590B1 (en) | 2000-07-03 | 2003-07-01 | Marine Bioproducts International | Clarified hydrocolloids of undiminished properties and method of producing same |
| US7408057B2 (en) * | 2000-07-03 | 2008-08-05 | Marine Bioproducts Intenational | Clarified hydrocolloids of undiminished properties and method of producing same |
| EP1730516A1 (en) * | 2004-03-30 | 2006-12-13 | Pfizer Products Incorporated | Method and device for evaluation of pharmaceutical compositions |
| US7956180B2 (en) * | 2004-05-27 | 2011-06-07 | Novozymes A/S | Dried and agglomerated hyaluronic acid product |
| CA2567722C (en) | 2004-05-27 | 2013-06-18 | Novozymes Biopolymer A/S | A dried and agglomerated hyaluronic acid product |
| WO2008065502A1 (en) * | 2006-11-29 | 2008-06-05 | Pfizer Products Inc. | Pharmaceutical compositions based on a) nanoparticles comprising enteric polymers and b) casein |
| US20100119612A1 (en) * | 2007-04-17 | 2010-05-13 | Bend Research, Inc | Nanoparticles comprising non-crystalline drug |
| WO2008135855A2 (en) * | 2007-05-03 | 2008-11-13 | Pfizer Products Inc. | Nanoparticles comprising a cholesteryl ester transfer protein inhibitor and a nonionizable polymer |
| WO2008135852A2 (en) * | 2007-05-03 | 2008-11-13 | Pfizer Products Inc. | Pharmaceutical compositions comprising nanoparticles and casein |
| WO2008135828A2 (en) * | 2007-05-03 | 2008-11-13 | Pfizer Products Inc. | Nanoparticles comprising a drug, ethylcellulose, and a bile salt |
| EP2162120B1 (en) * | 2007-06-04 | 2016-05-04 | Bend Research, Inc | Nanoparticles comprising a non-ionizable cellulosic polymer and an amphiphilic non-ionizable block copolymer |
| US9545384B2 (en) | 2007-06-04 | 2017-01-17 | Bend Research, Inc. | Nanoparticles comprising drug, a non-ionizable cellulosic polymer and tocopheryl polyethylene glocol succinate |
| US20100215747A1 (en) * | 2007-07-13 | 2010-08-26 | Corey Jay Bloom | Nanoparticles comprising ionizable, poorly water soluble cellulosic polymers |
| US9233078B2 (en) * | 2007-12-06 | 2016-01-12 | Bend Research, Inc. | Nanoparticles comprising a non-ionizable polymer and an Amine-functionalized methacrylate copolymer |
| WO2009073215A1 (en) * | 2007-12-06 | 2009-06-11 | Bend Research, Inc. | Pharmaceutical compositions comprising nanoparticles and a resuspending material |
| MX2011007714A (es) | 2009-02-05 | 2011-12-06 | Alcon Res Ltd | Proceso para purificar goma guar. |
| FR2942585B1 (fr) * | 2009-03-02 | 2011-04-29 | Roquette Freres | Poudre granulee contenant des proteines vegetales et des fibres, leur procede d'obtention et leurs utilisations |
| TWI547522B (zh) * | 2009-07-07 | 2016-09-01 | 愛爾康研究有限公司 | 環氧乙烷環氧丁烷嵌段共聚物組成物 |
Family Cites Families (23)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US2196768A (en) * | 1938-03-11 | 1940-04-09 | Eastman Kodak Co | Enteric coating |
| DE1468014A1 (de) * | 1964-01-29 | 1969-01-09 | Henkel & Cie Gmbh | Verfahren zur Herstellung von Hydroxyalkylaethern von Galactomannanen |
| US3573058A (en) * | 1967-01-30 | 1971-03-30 | Swift & Co | Microcrystalline cellulose compositions co-dried with hydrocolloids |
| US3679658A (en) * | 1970-02-03 | 1972-07-25 | Gen Mills Inc | Calcium carboxylalkyl ethers of galactomannan gums |
| US3912713A (en) * | 1973-08-29 | 1975-10-14 | Scholten Honig Research Nv | Guar gum derivatives and process for preparation |
| US4011393A (en) * | 1975-04-28 | 1977-03-08 | Celanese Corporation | Polygalactomannan gum formate esters |
| US4043952A (en) * | 1975-05-09 | 1977-08-23 | National Starch And Chemical Corporation | Surface treatment process for improving dispersibility of an absorbent composition, and product thereof |
| SE418247B (sv) * | 1975-11-17 | 1981-05-18 | Haessle Ab | Sett att framstella kroppar med reglerad frigoring av en aktiv komponent |
| US4031306A (en) * | 1975-12-15 | 1977-06-21 | Celanese Corporation | Polygalactomannan allyl ether compositions |
| NZ191102A (en) * | 1978-07-25 | 1982-03-09 | Wellcome Found | Pharmaceutical formulations of galactomannan |
| US4309535A (en) * | 1980-01-21 | 1982-01-05 | Hercules Incorporated | Method of improving dispersibility of anionic cellulose ethers |
| US4299825A (en) * | 1980-07-03 | 1981-11-10 | Celanese Corporation | Concentrated xanthan gum solutions |
| JPS57120518A (en) * | 1981-01-19 | 1982-07-27 | Tanabe Seiyaku Co Ltd | Preparation of microcapsule |
| EP0064485B1 (en) * | 1981-04-27 | 1985-07-24 | Aktiebolaget Hässle | New pharmaceutical preparation |
| SE8103843L (sv) * | 1981-06-18 | 1982-12-19 | Astra Laekemedel Ab | Farmaceutisk mixtur |
| CH652930A5 (de) * | 1983-03-25 | 1985-12-13 | Wheli Inter Ag | Polysaccharid-agglomerat. |
| US4551331A (en) * | 1983-06-02 | 1985-11-05 | S. C. Johnson & Son, Inc. | Easily dispersible dietary fiber product and method for producing the same |
| US4608278A (en) * | 1983-06-22 | 1986-08-26 | The Ohio State University Research Foundation | Small particule formation and encapsulation |
| US4551347A (en) * | 1983-09-14 | 1985-11-05 | Nabisco Brands, Inc. | Process of preparing instant, flaked, wheat farina |
| US4619831A (en) * | 1984-06-04 | 1986-10-28 | Warner-Lambert Company | Dietary fiber composition and process of manufacture |
| US4606940A (en) * | 1984-12-21 | 1986-08-19 | The Ohio State University Research Foundation | Small particle formation and encapsulation |
| SE8501365L (sv) * | 1985-03-20 | 1986-09-21 | Lejus Medical Ab | Forfarande for overdragning av granuler; piller och tabletter |
| US4666705A (en) * | 1985-06-03 | 1987-05-19 | E. R. Squibb & Sons, Inc. | Controlled release formulation |
-
1985
- 1985-06-20 SE SE8503092A patent/SE458576B/sv unknown
-
1986
- 1986-06-17 DE DE8686850218T patent/DE3683412D1/de not_active Expired - Lifetime
- 1986-06-17 EP EP86850218A patent/EP0207032B1/en not_active Expired - Lifetime
- 1986-06-17 AT AT86850218T patent/ATE71493T1/de active
- 1986-06-18 FI FI862602A patent/FI88101C/fi not_active IP Right Cessation
- 1986-06-19 DK DK287386A patent/DK162624C/da not_active IP Right Cessation
- 1986-06-19 NO NO862459A patent/NO164913C/no unknown
- 1986-06-20 US US06/877,007 patent/US4754027A/en not_active Expired - Fee Related
Also Published As
| Publication number | Publication date |
|---|---|
| EP0207032A2 (en) | 1986-12-30 |
| SE8503092D0 (sv) | 1985-06-20 |
| EP0207032B1 (en) | 1992-01-15 |
| DK287386A (da) | 1986-12-21 |
| DK162624C (da) | 1992-04-13 |
| SE8503092L (da) | 1986-12-21 |
| US4754027A (en) | 1988-06-28 |
| NO862459L (no) | 1986-12-22 |
| SE458576B (sv) | 1989-04-17 |
| NO164913B (no) | 1990-08-20 |
| NO164913C (no) | 1990-11-28 |
| FI88101C (fi) | 1993-04-13 |
| FI862602A0 (fi) | 1986-06-18 |
| DE3683412D1 (de) | 1992-02-27 |
| DK287386D0 (da) | 1986-06-19 |
| EP0207032A3 (en) | 1989-01-25 |
| FI862602L (fi) | 1986-12-21 |
| NO862459D0 (no) | 1986-06-19 |
| FI88101B (fi) | 1992-12-31 |
| ATE71493T1 (de) | 1992-02-15 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| DK162624B (da) | Fremgangsmaade til fremstilling af et guargummi-holdigt produkt | |
| Sriamornsak | Chemistry of pectin and its pharmaceutical uses: A review | |
| EP2120602B2 (en) | Process for producing slowly digestible starch | |
| CN101802018B (zh) | 制备含有纤维的果胶产品的方法及果胶产品 | |
| Patel et al. | Guar gum: a versatile material for pharmaceutical industries | |
| Wurzburg | Modified starches | |
| HUP0300409A2 (hu) | Antiadhezív szénhidrátokat tartalmazó gyógyszerkészítmények és alkalmazásuk | |
| CN1284533C (zh) | 具有高直链淀粉含量的乙酰化预凝胶化淀粉的用途 | |
| Silveira et al. | Pharmaceutical use of galactomannans | |
| Onofre et al. | Hydroxypropylated starches of varying amylose contents as sustained release matrices in tablets | |
| GB2367002A (en) | Coating composition | |
| Günter et al. | Swelling behavior and satiating effect of the gel microparticles obtained from callus cultures pectins | |
| Sopyan et al. | Overview of pectin as an excipient and its use in the pharmaceutical dosage form | |
| Ren et al. | Design and preparation of a novel colon-targeted tablet of hydrocortisone | |
| JP5875196B2 (ja) | 結腸ターゲッティング用の不消化性ポリマー：デンプンアセテート系フィルムコーティング | |
| Liu et al. | Characterization of glucans from diverse sources and their influence on fat and carbohydrate absorption, digestion in vitro, and glucose tolerance in vivo | |
| Ren et al. | Design and preparation of a novel colon-targeted tablet of hydrocortisone | |
| YUSRIADI et al. | THE EFFECT OF BANGGAI YAM (DIOSCOREA ALATA L.) MODIFICATION ON FILM CHARACTERISTICS AS A FILM COATING MATERIAL FOR MODIFIED RELEASE DOSAGE FORMS | |
| Das et al. | Acid Hydrolysed Starch for Drug Delivery System: A Review | |
| Freichel et al. | Artificially induced polymer particle erosion of oral hydrocolloid systems by the addition of insoluble cellulose fibres to fibre-free methylhydroxy ethylcellulose (MHEC) | |
| Sundar Raj et al. | A Review on Pectin: Chemistry due to General Properties of Pectin and its Pharmaceutical Uses. 1: 550 doi: 10.4172/scientificreports. 550 Page 2 of 4 Volume 1• Issue 12• 2012 in a chain-like configuration; this corresponds to average molecular weights from about 50,000 to 150,000 daltons | |
| Kaur et al. | P. Glucomannans and galactomannans: drug delivery | |
| CN116075240A (zh) | 用于治疗代谢综合征的具有新兴特性的新系统 | |
| Sheng et al. | Inhibitory Effects of Water-Soluble Hemicelluloses with Different Molecular Weights on the Digestibility of Wheat Starch |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PUP | Patent expired |